US6924128B2
(en)
|
1994-12-06 |
2005-08-02 |
Targeted Genetics Corporation |
Packaging cell lines for generation of high titers of recombinant AAV vectors
|
AU4645697A
(en)
|
1996-09-11 |
1998-04-02 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Aav4 vector and uses thereof
|
US6995006B2
(en)
|
1997-09-05 |
2006-02-07 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
CA2745131C
(en)
|
1998-05-28 |
2016-08-09 |
John A. Chiorini |
Aav5 vector and uses thereof
|
US6759237B1
(en)
|
1998-11-05 |
2004-07-06 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
|
US6491907B1
(en)
|
1998-11-10 |
2002-12-10 |
The University Of North Carolina At Chapel Hill |
Recombinant parvovirus vectors and method of making
|
WO2001025253A2
(en)
|
1999-10-01 |
2001-04-12 |
The University Of North Carolina At Chapel Hill |
Temperature-sensitive regulation of viral vector production
|
DE10120265A1
(de)
*
|
2001-04-25 |
2002-11-14 |
Deutsches Krebsforsch |
AAV-Helferplasmide zur Helfervirus-freien Verpackung und Pseudotypisierung von AAV-Vektoren
|
AU2008202344B2
(en)
*
|
2001-11-13 |
2011-08-25 |
The Trustees Of The University Of Pennsylvania |
A method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
|
ATE520707T1
(de)
*
|
2001-11-13 |
2011-09-15 |
Univ Pennsylvania |
Verfahren für den nachweis und/oder die identifikation von sequenzen des adeno- assoziierten virus (aav) sowie isolation von dadurch identifizierten, neuen sequenzen
|
ES2371546T3
(es)
*
|
2001-11-13 |
2012-01-05 |
The Trustees Of The University Of Pennsylvania |
Un procedimiento de detección y/o identificación de secuencias de virus adeno-asociados (aav) y aislamiento de nuevas secuencias as�? identificadas.
|
ES2526341T3
(es)
*
|
2001-12-17 |
2015-01-09 |
The Trustees Of The University Of Pennsylvania |
Secuencias de serotipo 9 de virus adeno-asociado (AAV), vectores que las contienen, y usos de las mismas
|
EP2359869B1
(de)
|
2001-12-17 |
2018-12-26 |
The Trustees Of The University Of Pennsylvania |
Sequenzen von Adeno-assoziierte Viren (AAV) vom Serotyp 8, Vektoren enthaltend solche Sequenzen und Verwendungen dafür
|
JP2005532789A
(ja)
|
2002-03-15 |
2005-11-04 |
ワイス・ホールデイングス・コーポレーシヨン |
減少した酵素活性を有する型別不能なインフルエンザ菌(Haemophilusinfluenza)のP4タンパク質の変異体
|
US7419817B2
(en)
|
2002-05-17 |
2008-09-02 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. |
Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
|
US8927269B2
(en)
|
2003-05-19 |
2015-01-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Avian adenoassociated virus and uses thereof
|
EP2298926A1
(de)
|
2003-09-30 |
2011-03-23 |
The Trustees of The University of Pennsylvania |
Claden (Subtypen) und Sequenzen von Adeno-Assoziiertem Virus (AAV), diese enthaltende Vektoren und ihre Verwendungen
|
WO2005056807A2
(en)
|
2003-12-04 |
2005-06-23 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health |
Bovine adeno-associated viral (baav) vector and uses thereof
|
ES2442225T3
(es)
|
2004-04-28 |
2014-02-10 |
The Trustees Of The University Of Pennsylvania |
Régimen de inmunización con cebado de adenovirus suprimido en E4 y potenciación de adenovirus suprimido en E1
|
DE602005026269D1
(de)
|
2004-04-28 |
2011-03-24 |
Univ Pennsylvania |
Sequenzielle freisetzung immunogener moleküle über adenoviren und adeno-assoziierte viren vermittelte abgaben
|
NZ555830A
(en)
|
2004-12-15 |
2009-01-31 |
Univ North Carolina |
Chimeric vectors
|
EP3409296A1
(de)
|
2005-04-07 |
2018-12-05 |
The Trustees of the University of Pennsylvania |
Verfahren zur erhöhung der funktion eines aav-vektors
|
WO2006119432A2
(en)
|
2005-04-29 |
2006-11-09 |
The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services |
Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
|
EP1979485A2
(de)
*
|
2006-01-31 |
2008-10-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Selbstkomplementäre parvovirale vektoren und verfahren zur herstellung und verwendung davon
|
US9198984B2
(en)
|
2006-04-28 |
2015-12-01 |
The Trustees Of The University Of Pennsylvania |
Scalable production method for AAV
|
US8221738B2
(en)
|
2008-02-19 |
2012-07-17 |
Celladon Corporation |
Method for enhanced uptake of viral vectors in the myocardium
|
EP2396343B1
(de)
|
2009-02-11 |
2017-05-17 |
The University of North Carolina At Chapel Hill |
Modifizierte virusvektoren sowie verfahren zu ihrer herstellung und verwendung
|
MX2011010097A
(es)
|
2009-03-27 |
2011-10-19 |
Proyecto Biomedicina Cima Sl |
Metodos y composiciones para el tratamiento de cirrosis y fibrosis hepatica.
|
MX2012005340A
(es)
|
2009-11-05 |
2012-12-05 |
Proyecto Biomedicina Cima Sl |
Sistemas de expresion regulada.
|
EP2524037B1
(de)
|
2010-01-12 |
2018-05-16 |
The University Of North Carolina At Chapel Hill |
Restriktive umgekehrte endverstärkungen für virusvektoren
|
CA3128549A1
(en)
|
2010-07-12 |
2012-01-19 |
Universitat Autonoma De Barcelona |
Gene therapy composition for use in diabetes treatment
|
CN107828820B
(zh)
*
|
2010-10-27 |
2022-06-07 |
学校法人自治医科大学 |
用于向神经系统细胞导入基因的腺相关病毒粒子
|
WO2012109570A1
(en)
|
2011-02-10 |
2012-08-16 |
The University Of North Carolina At Chapel Hill |
Viral vectors with modified transduction profiles and methods of making and using the same
|
KR20220056884A
(ko)
|
2011-04-22 |
2022-05-06 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
변이체 캡시드를 지니는 아데노-관련 바이러스 및 이의 사용 방법
|
EP2692868A1
(de)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adenoassoziierte virale (AAV) Vektoren für die Transduktion von Fettgewebe
|
CN111621507A
(zh)
|
2012-09-28 |
2020-09-04 |
北卡罗来纳-查佩尔山大学 |
靶向少突胶质细胞的aav载体
|
EP3517612A1
(de)
|
2013-03-15 |
2019-07-31 |
The University of North Carolina At Chapel Hill |
Synthetische adenoassoziierte virusinvertierte endwiederholungssequenzen
|
AU2014227766B2
(en)
|
2013-03-15 |
2018-10-04 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for dual glycan binding AAV vectors
|
WO2014201252A2
(en)
|
2013-06-13 |
2014-12-18 |
Shire Human Genetic Therapies, Inc. |
Messenger rna based viral production
|
RU2705249C2
(ru)
*
|
2013-07-12 |
2019-11-06 |
Дзе Чилдрен'З Хоспитал Оф Филадельфия |
Вектор aav и анализ на нейтрализующие антитела против aav (аденоассоциированного вируса)
|
US20160354489A1
(en)
|
2013-09-26 |
2016-12-08 |
Universitat Autònome de Barcelona |
Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease
|
GB201403684D0
(en)
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
CA2939950C
(en)
|
2014-03-09 |
2023-08-22 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency
|
US9458464B2
(en)
|
2014-06-23 |
2016-10-04 |
The Johns Hopkins University |
Treatment of neuropathic pain
|
US10973931B2
(en)
|
2014-09-16 |
2021-04-13 |
Universitat Autònoma De Barcelona |
Adeno-associated viral vectors for the gene therapy of metabolic diseases
|
RU2727015C2
(ru)
|
2014-11-21 |
2020-07-17 |
Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл |
Векторы aav, нацеленные на центральную нервную систему
|
ES2900973T3
(es)
|
2015-01-07 |
2022-03-21 |
UNIV AUTòNOMA DE BARCELONA |
Constructo genético de vector individual que comprende genes de insulina y glucoquinasa
|
CA2972807C
(en)
|
2015-01-14 |
2024-01-16 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for targeted gene transfer
|
MX2017010117A
(es)
|
2015-02-06 |
2018-05-17 |
Univ North Carolina Chapel Hill |
Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso.
|
CA2996420A1
(en)
|
2015-09-28 |
2017-04-06 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for antibody-evading virus vectors
|
RU2743792C2
(ru)
|
2015-11-05 |
2021-02-26 |
Бамбу Терапьютикс, Инк. |
Модифицированные гены атаксии фридрейха и векторы для генной терапии
|
WO2017160360A2
(en)
|
2015-12-11 |
2017-09-21 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav9
|
US11015173B2
(en)
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV1
|
WO2017100704A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aavrh10
|
EP4215605A1
(de)
|
2015-12-11 |
2023-07-26 |
The Trustees of The University of Pennsylvania |
Skalierbares reinigungsverfahren für aav8
|
LT3411484T
(lt)
|
2016-02-05 |
2023-11-27 |
Emory University |
Viengrandžio arba sau pačiam komplementaraus adeno-asocijuoto viruso 9 injekcija į smegenų skystį
|
JP7231922B2
(ja)
|
2016-02-22 |
2023-03-02 |
ザ ユニヴァーシティー オブ ノース カロライナ アト チャペル ヒル |
Mps-i関連失明の治療のためのaav-iduaベクター
|
EP3449250B1
(de)
|
2016-04-28 |
2020-11-04 |
Indiana University Research & Technology Corporation |
Verfahren und zusammensetzungen zur auflösung von komponenten einer viruspräparation
|
EP4049683A1
(de)
|
2016-04-29 |
2022-08-31 |
Adverum Biotechnologies, Inc. |
Evasion von neutralisierenden antikörpern durch ein rekombinantes adeno-assoziiertes virus
|
WO2017189959A1
(en)
*
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
US11299751B2
(en)
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
EP3448875A4
(de)
*
|
2016-04-29 |
2020-04-08 |
Voyager Therapeutics, Inc. |
Zusammensetzungen zur behandlung einer erkrankung
|
US11866462B2
(en)
*
|
2016-05-04 |
2024-01-09 |
Oregon Health & Science University |
Recombinant adeno-associated viral vectors
|
WO2017197355A2
(en)
|
2016-05-13 |
2017-11-16 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and methods of use thereof
|
US11504435B2
(en)
|
2016-06-13 |
2022-11-22 |
The University Of North Carolina At Chapel Hill |
Optimized CLN1 genes and expression cassettes and their use
|
CA2971303A1
(en)
|
2016-06-21 |
2017-12-21 |
Bamboo Therapeutics, Inc. |
Optimized mini-dystrophin genes and expression cassettes and their use
|
EP3491015A4
(de)
|
2016-07-26 |
2020-02-26 |
The University of North Carolina at Chapel Hill |
Vektorvermittelte immuntoleranz im auge
|
WO2018075798A1
(en)
|
2016-10-19 |
2018-04-26 |
Adverum Biotechnologies, Inc. |
Modified aav capsids and uses thereof
|
EP3535396A1
(de)
|
2016-11-01 |
2019-09-11 |
Novartis AG |
Verfahren und zusammensetzungen zur verbesserung der genbearbeitung
|
WO2018134168A1
(en)
|
2017-01-17 |
2018-07-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of expressing a polynucleotide of interest in the cone photoreceptors
|
JP2020510424A
(ja)
*
|
2017-02-28 |
2020-04-09 |
アドヴェラム バイオテクノロジーズ, インコーポレイテッド |
改変aavカプシドおよびその使用
|
JP7132934B2
(ja)
|
2017-03-15 |
2022-09-07 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
ポリプロイド性アデノ随伴ウイルスベクターならびにその作製および使用の方法
|
EP3388520A1
(de)
|
2017-04-11 |
2018-10-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzung zur reduzierung der expression von nkcc1 in einer darauf angewiesenen person
|
CN110945018A
(zh)
|
2017-07-27 |
2020-03-31 |
诺华股份有限公司 |
抗脱落酶的trem2变体
|
RU2770922C2
(ru)
|
2017-09-20 |
2022-04-25 |
4Д Молекьюлар Терапьютикс Инк. |
Капсиды вариантов аденоассоциированных вирусов и методы их применения
|
EP3685168A1
(de)
|
2017-09-20 |
2020-07-29 |
The Trustees Of Indiana University |
Verfahren zur auflösung von lipoproteinen mit massenspektrometrie
|
WO2019077159A1
(en)
|
2017-10-20 |
2019-04-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS OF EXPRESSING POLYNUCLEOTIDE OF INTEREST IN CONE PHOTORECCEPTORS OF A SUBJECT COMPRISING SUB-RETINAL ADMINISTRATION OF A THERAPEUTICALLY EFFECTIVE AMOUNT OF A RECOMBINANT AAV9 DERIVATIVE VECTOR
|
WO2019094061A1
(en)
|
2017-11-07 |
2019-05-16 |
The University Of North Carolina At Chapel Hill |
Optimized aga genes and expression cassettes and their use
|
CA3083472A1
(en)
|
2017-11-27 |
2019-05-31 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and use for inhibiting angiogenesis
|
US11232941B2
(en)
|
2018-01-12 |
2022-01-25 |
The Trustees Of Indiana University |
Electrostatic linear ion trap design for charge detection mass spectrometry
|
KR20200123201A
(ko)
|
2018-02-21 |
2020-10-28 |
알시온 라이프사이언스 인크. |
유체 전달 시스템 및 방법
|
CA3095179A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
JP7406677B2
(ja)
|
2018-04-03 |
2023-12-28 |
ギンコ バイオワークス インコーポレイテッド |
抗体を回避するウイルスベクター
|
KR20210006358A
(ko)
|
2018-04-03 |
2021-01-18 |
스트라이드바이오 인코포레이티드 |
안 조직을 표적으로 하기 위한 바이러스 벡터
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
JP7398810B2
(ja)
|
2018-06-04 |
2023-12-15 |
ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー |
静電線形イオン・トラップにイオンを捕獲する装置および方法
|
JP7306727B2
(ja)
|
2018-06-04 |
2023-07-11 |
ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー |
リアル・タイム分析および信号最適化による電荷検出質量分光分析法
|
KR20210035102A
(ko)
|
2018-06-04 |
2021-03-31 |
더 트러스티즈 오브 인디애나 유니버시티 |
높은 스루풋 전하 검출 질량 분광분석법을 위한 이온 트랩 어레이
|
WO2019236143A1
(en)
|
2018-06-04 |
2019-12-12 |
The Trustees Of Indiana University |
Apparatus and method for calibrating or resetting a charge detector
|
WO2019236139A1
(en)
|
2018-06-04 |
2019-12-12 |
The Trustees Of Indiana University |
Interface for transporting ions from an atmospheric pressure environment to a low pressure environment
|
EP3807404A1
(de)
|
2018-06-13 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Manipulierte 5'-unübersetzte regionen (5' utr) zur herstellung von aav
|
US20210269829A1
(en)
|
2018-06-28 |
2021-09-02 |
The University Of North Carolina At Chapel Hill |
Optimized cln5 genes and expression cassettes and their use
|
US20210355454A1
(en)
|
2018-07-24 |
2021-11-18 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
US20210316012A1
(en)
|
2018-08-10 |
2021-10-14 |
The University Of North Carolina At Chapel Hill |
Optimized cln7 genes and expression cassettes and their use
|
JP2021536289A
(ja)
|
2018-08-27 |
2021-12-27 |
アルキオーネ・ライフサイエンシズ・インコーポレイテッドAlcyone Lifesciences, Inc. |
流体送達システムおよび方法
|
TW202035689A
(zh)
|
2018-10-04 |
2020-10-01 |
美商航海家醫療公司 |
測量病毒載體粒子的效價及強度之方法
|
CA3115248A1
(en)
|
2018-10-05 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding aav production proteins
|
CN113166781A
(zh)
|
2018-10-15 |
2021-07-23 |
沃雅戈治疗公司 |
在杆状病毒/Sf9系统中大规模生产rAAV的表达载体
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
AU2019384065A1
(en)
|
2018-11-20 |
2021-06-03 |
The Trustees Of Indiana University |
Orbitrap for single particle mass spectrometry
|
CA3118567A1
(en)
|
2018-12-03 |
2020-06-11 |
The Trustees Of Indiana University |
Apparatus and method for simultaneously analyzing multiple ions with an electrostatic linear ion trap
|
CR20210444A
(es)
|
2019-02-25 |
2021-11-02 |
Novartis Ag |
Composiciones y métodos para tratar distrofia cristalina de bietti
|
WO2020174369A2
(en)
|
2019-02-25 |
2020-09-03 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
TW202102525A
(zh)
|
2019-03-21 |
2021-01-16 |
美商史崔德生物公司 |
重組腺相關病毒載體
|
EP3959741A1
(de)
|
2019-04-23 |
2022-03-02 |
The Trustees of Indiana University |
Identifizierung von probensubspezies basierend auf partikelladungsverhalten unter strukturveränderungen induzierenden probenbedingungen
|
US20220280655A1
(en)
|
2019-04-23 |
2022-09-08 |
Institut National de la Santé et de la Recherche Médicale |
New Adeno-Associated Virus (AAV) Variants and Uses Thereof for Gene Therapy
|
AU2020261435A1
(en)
|
2019-04-26 |
2021-11-25 |
Sangamo Therapeutics, Inc. |
Engineering AAV
|
CN113767110A
(zh)
|
2019-04-26 |
2021-12-07 |
北卡罗来纳-查佩尔山大学 |
用于双重聚糖结合aav2.5载体的方法和组合物
|
PE20212357A1
(es)
|
2019-05-24 |
2021-12-17 |
Regeneron Pharma |
Particulas virales modificadas y usos de estas
|
WO2020261178A1
(en)
|
2019-06-27 |
2020-12-30 |
Pfizer Inc. |
Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
|
CN114502590A
(zh)
|
2019-09-18 |
2022-05-13 |
诺华股份有限公司 |
Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
GB201913974D0
(en)
|
2019-09-27 |
2019-11-13 |
King S College London |
Vector
|
TW202128736A
(zh)
|
2019-10-17 |
2021-08-01 |
美商史崔德生物公司 |
用於治療c型尼曼—匹克病之腺相關病毒載體
|
EP4110373A1
(de)
|
2020-02-28 |
2023-01-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Gentherapie für ahornsirup-urinerkrankung
|
WO2021188960A1
(en)
|
2020-03-20 |
2021-09-23 |
University Of Florida Research Foundation, Inc. |
Gene therapy for cockayne syndrome
|
US20240043494A1
(en)
|
2020-08-07 |
2024-02-08 |
Amicus Therapeutics, Inc. |
Vesicle Targeting Proteins And Uses Of Same
|
WO2022093769A1
(en)
|
2020-10-28 |
2022-05-05 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for dual glycan binding aav2.5 vector
|
AU2021369480A1
(en)
|
2020-10-28 |
2023-04-20 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for dual glycan binding AAV2.5 vector
|
MX2023005218A
(es)
|
2020-11-03 |
2023-05-16 |
Pfizer |
Metodos de purificacion de vectores de aav mediante cromatografia de intercambio anionico.
|
WO2022130172A1
(en)
|
2020-12-15 |
2022-06-23 |
Pfizer Inc. |
Hilic uplc-ms method for separating and analyzing intact adeno-associated virus capsid proteins
|
AU2021404944A1
(en)
|
2020-12-23 |
2023-07-06 |
Pfizer Inc. |
Methods for purification of aav vectors by affinity chromatography
|
TW202242124A
(zh)
|
2021-01-14 |
2022-11-01 |
美商史崔德生物公司 |
靶向t細胞之aav載體
|
BR112023015303A2
(pt)
|
2021-02-01 |
2023-11-14 |
Regenxbio Inc |
Método para tratar doença cln2 devido a deficiência de tpp1 em um sujeito
|
WO2022208342A1
(en)
|
2021-04-01 |
2022-10-06 |
Pfizer Inc. |
Pharmaceutical compositions containing adeno-associated viral vector
|
US20240189447A1
(en)
|
2021-04-16 |
2024-06-13 |
Asklepios Biopharmaceutical, Inc. |
Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
|
CN117377500A
(zh)
|
2021-04-26 |
2024-01-09 |
阿雷克森国际制药有限公司 |
具有改善的组织向性的腺相关病毒载体衣壳
|
BR112023024375A2
(pt)
|
2021-05-28 |
2024-02-15 |
Shanghai Regenelead Therapies Co Ltd |
Vírus adeno-associado recombinante tendo capsídeo variante e sua aplicação
|
WO2022269466A1
(en)
|
2021-06-22 |
2022-12-29 |
Pfizer Inc. |
Production of adeno-associated virus vector in insect cells
|
EP4363437A1
(de)
|
2021-07-01 |
2024-05-08 |
Amicus Therapeutics, Inc. |
Neurotensinvarianten und markierte proteine mit neurotensin oder sortilin-propeptid
|
IL309742A
(en)
|
2021-07-08 |
2024-02-01 |
Tenaya Therapeutics Inc |
Optimal expression cassettes for gene therapy
|
AU2022327583A1
(en)
|
2021-08-11 |
2024-02-22 |
King's College London |
Compositions and methods for improved treatment of disorders affecting the central nervous system
|
WO2023069987A1
(en)
|
2021-10-20 |
2023-04-27 |
University Of Rochester |
Rejuvenation treatment of age-related white matter loss cross reference to related application
|
WO2023081633A1
(en)
|
2021-11-02 |
2023-05-11 |
University Of Rochester |
Tcf7l2 mediated remyelination in the brain
|
CA3233698A1
(en)
|
2021-11-04 |
2023-05-11 |
Regeneron Pharmaceuticals, Inc. |
Viral particles retargeted to skeletal muscle
|
WO2023114816A1
(en)
|
2021-12-14 |
2023-06-22 |
Neurogene, Inc. |
Recombinant optimized galc constructs and methods for treating galc-associated disorders
|
GB202201242D0
(en)
|
2022-01-31 |
2022-03-16 |
Univ Edinburgh |
Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
|
WO2023150687A1
(en)
|
2022-02-04 |
2023-08-10 |
Ginkgo Bioworks, Inc. |
Recombinant adeno-associated virus vectors, and methods of use thereof
|
WO2023201207A1
(en)
|
2022-04-11 |
2023-10-19 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
GB202206336D0
(en)
|
2022-04-29 |
2022-06-15 |
Univ Edinburgh |
Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
|
WO2023214346A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
WO2023220603A1
(en)
|
2022-05-09 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
WO2024003687A1
(en)
|
2022-06-28 |
2024-01-04 |
Pfizer Inc. |
Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
|
WO2024026494A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Viral particles retargeted to transferrin receptor 1
|
WO2024038365A1
(en)
|
2022-08-16 |
2024-02-22 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
WO2024107765A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
WO2024124019A2
(en)
|
2022-12-07 |
2024-06-13 |
Ginkgo Bioworks, Inc. |
Aav vectors targeting hematopoietic stem cells
|
WO2024130175A2
(en)
|
2022-12-16 |
2024-06-20 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind to aav particles and uses
|